High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes

Aug.03.2022
High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes
One-time use Puff e-cigarettes contain high levels of unknown chemicals and synthetic coolants that are toxic to human cells.

A picture of a disposable puff electronic cigarette from Talbot Lab at the University of California, Riverside. Electronic cigarettes (EC) contain nicotine, solvents, and flavored chemicals, and are particularly popular among young people. In 2020, the US Food and Drug Administration (FDA) banned flavored EC pods based on cartridges, but this ban did not extend to "disposable" flavored EC products, such as Puff EC. Unfortunately, the chemical composition and toxicity of the liquid in Puff ECs is largely unknown.


Researchers from the University of California Riverside and Portland State University have examined 16 disposable Puff devices to determine their flavor chemicals, synthetic cooling agents, and nicotine concentrations. One of the synthetic cooling agents tested is WS-23 which provides a cooling sensation.


A team used gas chromatography and mass spectrometry to identify 126 flavor chemicals in Puff EC liquid and tested their toxicity on human bronchial epithelial cells. They reported in the journal Toxicology and Chemistry that the chemical content in single-use Puff EC was high and had cytotoxicity or toxicity to living cells.


Our data supports the need to regulate the flavoring chemicals and synthetic cooling agents in Puff EC to limit their potentially harmful effects on health," said Esther Omaiye, a former graduate student in the Environmental Toxicology Graduate Program and first author of the research paper. "The levels of nicotine, flavoring chemicals, and synthetic cooling agents in Puff EC are higher than those found in other consumer products, raising concerns about the safety of Puff products.


Omaiye, a postdoctoral researcher in the Prue Talbot laboratory, stated that one of the areas of regulatory concern related to e-cigarettes is the continuous development of novel chemicals in e-liquids.


For many years, we have been aware that EC design has been continuously evolving," said Talbot, the professor of cell biology leading the research team.


Recently, it has been discovered that chemicals used in e-cigarette liquids are changing. These changes are often made to make e-cigarette products more appealing to teenagers or to avoid regulation by the FDA, such as using synthetic nicotine instead of tobacco-derived nicotine to avoid FDA restrictions.


According to Talbot, the synthetic cooling agent WS-23, developed for use in shaving cream, is now included in EC liquids, but there is little information available about its inhalation toxicity.


Our work indicates that the concentration of WS-23 used in Puff ECs is sufficient to have negative long-term health effects," she said.


Other findings of the study include:


The EC in Puff contains a much higher concentration of synthetic cooling agents and flavor chemicals than JUUL EC.


Despite the unknown risks of inhaling, EC manufacturers are increasing the use and concentration of synthetic cooling agents, which is appealing to young users.


This article is compiled from third-party information and is intended only for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truth or accuracy of its contents. The compilation of this article is solely for industry exchange and research purposes.


Due to limitations in translation abilities, the compiled article may not fully express or accurately reflect the original text. Please refer to the original text for accuracy.


Regarding any domestic, Hong Kong, Macao, Taiwan, or international related statements and positions, 2FIRSTS fully aligns with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05